Pharma BD Deal Intelligence

Merck & Co. Inc. / Schering-Plough Corp.

2009 · Acquisition/Merger · $41.1B · Complete

Merck acquired Schering-Plough in a $41.1 billion reverse merger, gaining a diversified portfolio including Remicade, Nasonex, and the Vytorin/Zetia cholesterol franchise, creating the second-largest pharmaceutical company globally at the time.

Key facts

• Announced Mar 09, 2009
• Closed Nov 03, 2009
• Deal value $41.1B
• Deal type Acquisition/Merger
• Therapeutic area Cardiovascular, Gastroenterology, Immunology, Infectious Disease, Oncology, Respiratory
• Indications Hyperlipidemia, Rheumatoid arthritis, Crohn's disease, Allergic rhinitis, Hepatitis C
• Key assets Remicade (infliximab), Nasonex (mometasone), Vytorin (ezetimibe/simvastatin), Zetia (ezetimibe), PegIntron (peginterferon alfa-2b), Singulair (montelukast, Merck legacy), Organon BioSciences
• Mechanism Anti-TNF monoclonal antibody, Cholesterol absorption inhibitor, HMG-CoA reductase inhibitor, Corticosteroid, Pegylated interferon

← Browse all deals  ·  How we score deals